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phorylation of the carboxy-terminal tail 
by the atypical PKC (aPKC) prevents 
20S proteasomal degradation of SRC-3, 
negating the effects of p38 MAP kinase 
and GSK-3 activity. The net result of aPKC 
phosphorylation is the cellular accumula-
tion of the coactivator and enhanced ER-
dependent gene transcription. Interest-
ingly, other NRs such as the progesterone 
receptor do not exhibit a similar ability 
to trigger phosphorylation of SRC-3 by 
aPKC, highlighting the relevance of this 
mechanism to estrogen-dependent breast 
cancer cell growth. The authors show 
that the normal degradation of SRC-3 
involves an initial interaction with the C8 
alpha component of the 20S proteasome. 
However, when hyperphosphorylated by 
aPKC, SRC-3 undergoes a conformational 
change, exposing a negatively charged 
sequence that inhibits the interaction with 
C8 via electrostatic repulsion, effectively 
shielding it from the proteasome and 
resulting in a net increase in the cellular 
pool of this cofactor.
The relevance of this finding to breast 
cancer pathology is strengthened by the 
observation that SRC-3 phosphorylation 
by aPKC is promoted by hormone-acti-
vated ER. This leads to a proposal that 
estradiol binding to ER allows the recep-
tor to associate and stabilize the SRC-
3-aPKC dimer (Figure 1). The presump-
tive trimeric complex facilitates SRC-3 
phosphorylation, which in turn increases 
transcription of ER of target genes. Inter-
estingly, overexpression of aPKC has 
been observed in a number of cancers 
(Regala et al., 2005), which may pro-
vide an independent means to enhance 
SRC-3 pool size and ER transcription. 
Beyond NRs, SRC-3 has been shown to 
be a coactivator of other transcriptional 
networks, including activator protein-1 
(AP-1), nuclear factor-κB (NFκB), signal 
transducer and activator of transcription 
(STAT), and E2F1, all of which have been 
associated with cell growth and cancer 
(Liao et al., 2002). Thus, the work pre-
sented by Yi and colleagues provides us 
with a new model of how posttranslation 
modifications of a NR coactivator may 
promote cancer while offering a new ther-
apeutic target to exploit in its treatment.
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Tumor stem or initiating cells have been proposed to exist for melanoma. Stem-like cells have been propa-
gated from melanoma cell lines and specimens. Additionally, classical stem cell markers, including ABCG2 
and CD133, have been identified in clinical melanomas. However, definitive markers for the purification and 
further characterization of melanoma-initiating cells remained elusive. Recently, Schatton et al. provided solid 
evidence that the doxorubicin-resistant ATP-binding cassette transporter ABCB5 marks primitive cells capable 
of recapitulating melanomas in xenotransplantation models. The identification of melanoma-initiating cells has 
far-reaching implications, as new therapeutic strategies can be envisioned that specifically target these cells.A cancer stem cell hierarchy has been 
suggested to exist for melanomas in 
which primitive self-renewing melanoma 
cells, capable of initiating tumorigen-
esis, give rise to rapidly proliferating, 
more differentiated, and tumorigeni-
cally exhausted cells that constitute the 
bulk tumor population. Stem-like cells have been propagated from both cul-
tured melanoma cells and fresh clinical 
specimens as nonadherent spheres in 
stem cell-supportive media, similar to 
mammo- and neurospheres, that could 
self-renew, differentiate into various mes-
enchymal lineages, and initiate tumors in 
xenotransplantation models with small Cancercell number (Fang et al., 2005). Further-
more, stem cell properties, including 
side population, and stem cell makers, 
including ABCG2, CD133, and nestin, 
have been identified in melanomas (Dou 
et al., 2007; Grichnik et al., 2006; Klein et 
al., 2007; Monzani et al., 2007). Despite 
this suggestive evidence, in depth in  Cell 13, March 2008 ©2008 Elsevier Inc. 185
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vivo analysis of melanoma 
stem cells remained deficient. 
Markers that could specifically 
identify and purify putative mel-
anoma-initiating cells for fur-
ther characterization remained 
obscure. Recently, by applying 
in vivo methodologies previous 
utilized to identify and charac-
terize cancer stem cells from 
other malignancies, Schatton 
et al. have demonstrated that 
ABCB5+ melanoma cells are 
essential for melanoma induc-
tion and proliferation in xeno-
transplantation models (Schat-
ton et al., 2008).
Originally characterized as 
a regulator of cell-cell fusion 
of cultured progenitor mel-
anocytes by this same group 
(Frank et al., 2003), ABCB5 
was further shown to be a 
major efflux mediator of doxorubicin in 
melanomas (Frank et al., 2005). Moreover, 
ABCB5 was preferentially expressed 
on a distinct subset of chemoresistant 
CD133+ tumor cells (Frank et al., 2005), 
indicating that this ABC transporter may 
mark more primitive melanoma cells. 
Upon assessment of ABCB5 expression 
through tissue microarrays encompass-
ing the various stages of melanoma pro-
gression, significantly elevated levels of 
ABCB5+ cells were observed in primary 
and metastatic melanomas compared to 
benign nevi, suggesting that ABCB5 may 
be a marker of melanoma progression. 
Further analysis of ABCB5+ melanoma 
cells from freshly resected metastatic 
melanomas demonstrated a consistently 
identifiable subpopulation of ABCB5-
expressing cells ranging from approxi-
mately 2% to 20% of the total tumor 
population. Expression of ABCB5 also 
strongly overlapped with determinants 
of more primitive cells, including nes-
tin, TIE1, CD144, and BMPR1A, implying 
that ABCB5+ melanoma cells possess 
features of stem cells. Upon xenotrans-
plantation to a NOD/SCID mouse model, 
only ABCB5+ cells from either clinical 
melanomas or cultured melanoma cells 
consistently initiated tumors that were 
serially transplantable and capable of 
re-establishing the original parent tumor 
heterogeneity. Despite serial passage 
in mice, ABCB5 percentages remained 
similar to the original parent tumor and 
maintained coexpression of primitive cell 
markers, CD144 and TIE1.
Through clever in vivo lineage tracking 
of differentially fluorochome-conjugated 
cultured melanoma cells, co-xenografted 
ABCB5+ and ABCB5− subpopulations 
were assessed for their relative contri-
bution to tumor growth, self-renewal, 
and differentiation. Xenotransplantation 
of ABCB5+/DsRed and ABCB5−/EYFP 
cells to NOD/SCID mice reconstituted 
at a relative abundance of 1:5, respec-
tively, resulted in a dramatic increase 
in the frequency of DsRed+ tumor cells 
of ABCB5+ origin, up to 50% of the 
total tumor population by the end of 6 
weeks. These findings establish greater 
tumorigenicity of ABCB5+ subsets in a 
competitive tumor development model. 
Further analysis demonstrated that the 
majority of ABCB5+ cells were of DsRed 
phenotype, with insignificant numbers 
of double-positive cells, indicating that 
ABCB5+ cells arose exclusively from 
ABCB5+ cells, thus confirming the self-
renewal capacity of this subset. Addi-
tionally, ABCB5− isolates exhibited 
DsRed positivity, demonstrating that 
ABCB5+ cells possess the capacity to 
differentiate and give rise to ABCB5− 
tumor cells. Meanwhile, ABCB5−/YEFP 
cells gave rise exclusively to ABCB5− 
progeny, albeit at lower frequencies, 
suggesting that, although ABCB5− cells 
lacked the capacity to self-
renew, they still retained the 
capacity to undergo a lim-
ited number of replications 
prior to terminal differentia-
tion. Moreover, ABCB5− cells 
could not regenerate the 
ABCB5+ subset, suggesting 
that these cells lacked the 
capacity to self-renew. These 
findings confirm the existence 
of a tumor hierarchy in which 
ABCB5+ cells self-renew and 
give rise to more differentiated 
ABCB5− progeny.
To determine whether selec-
tive elimination of ABCB5+ 
cells, present among an 
unsegregated population of 
melanoma cells, could inhibit 
tumor formation, a monoclo-
nal anti-ABCB5 specific anti-
body regimen was adminis-
tered. Use of a nude mouse model, as 
opposed to a NOD/SCID mouse model, 
was ideal for this type of assessment, as 
nude mice are capable of IgG1-triggered 
immune effector responses, as well 
as antibody-dependent cell-mediated 
cytotoxicity. Regimented administra-
tion of anti-ABCB5 treatment prior to 
and following inoculation of tumorigenic 
cells significantly inhibited initial tumor 
formation and stunted the growth of 
established tumor cells, compared to 
control antibody treatment, which did 
not effect tumor formation. Antibody-
dependent cell-mediated cytotoxicity 
of ABCB5+ melanoma cells was deter-
mined to be the mechanism of inhibition. 
In the inoculated mice that established 
tumors despite anti-ABCB5 adminis-
tration, these tumors still contained 
ABCB5+ cells, suggesting that antibody 
treatment could not fully eradicate these 
cells once established. Notably how-
ever, among the mice treated with anti-
ABCB5 that failed to develop tumors, 
these mice remained tumor free for more 
than 8 months following antibody treat-
ment withdrawal, indicating that inhibi-
tion of melanoma-initiating cells can 
be potently effective long after treat-
ment has ceased. Although these data 
strongly indicate that ABCB5+ cells 
are essential for tumor induction, many 
clinical melanomas are identified sub-
sequent to melanoma establishment. 
figure 1. ABcB5 expression in a Melanoma stem cell Hierarchy
In the cancer stem cell hierarchy of melanoma, ABCB5+ melanoma-initiating 
cells give rise to more committed progenitor/transamplifying cells that may or 
may not express ABCB5, depending on the stage of differentiation, while ter-
minally differentiated cells lack expression of ABCB5. Tumorigenic potential is 
lost as these cells proceed toward differentiation as well as chemoresistance 
due to the downmodulation of ABCB5, a doxorubicin efflux transporter.
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in a more realistic scenario, anti-ABCB5 
treatment was undertaken on established 
melanoma xenografts. In vivo anti-ABCB5 
administration following tumor cell inocu-
lation considerably blocked tumor growth 
as compared to antibody control or 
untreated mice. Immunohistochemical 
analysis revealed foci of ABCB5 expres-
sion with macrophage infiltration corre-
sponding to in vivo bound anti-ABCB5 
monoclonal antibody that frequently 
bordered areas of necrosis. However, 
whether these tumors regain growth 
potential once antibody administration 
has ceased remains unknown.
Although ABCB5+ melanoma cells 
were enriched in tumor-initiating cells, 
at least 105 ABCB5+ cells were required 
for efficient tumor induction, suggest-
ing that not all ABCB5+ cells are equally 
tumorigenic. ABCB5+ melanoma cells 
may encompass self-renewing tumor-
initiating cells in addition to less primitive 
ABCB5+ progenitor cells, which may or 
may not be capable of self-renewal, but 
further give rise to ABCB5− terminally 
differentiated cells. The data by Schat-
ton et al. suggest that melanomas exist 
in a hierarchy in which ABCB5+ cells are 
the melanoma-initiating cells that give 
rise to progressively differentiated cells 
that lose ABCB5 expression as they 
reach terminal differentiation (Figure 1). 
However, it is not clear at which stage of differentiation ABCB5 is lost, leaving an 
alternative hypothesis in mind in which 
the melanoma-initiating cells could origi-
nate from a more committed ABCB5+ 
cell that has acquired mutations granting 
self-renewal capacity. Thus, ABCB5 in 
combination with other markers may be 
required to obtain a pure population of 
tumorigenic cells that also could distin-
guish among the various subsets within 
a melanoma hierarchy.
The expression of this chemoresis-
tant efflux transporter on melanoma-
initiating cells corroborates the inherent 
resistance of melanomas to many che-
motherapeutic interventions. Whether 
ABCB5 is the sole efflux transporter 
expressed by primitive melanoma cells 
or in combination with other ABC efflux 
transporters (La Porta, 2007) remains to 
be determined. Preferential expression 
of this transporter in this small popula-
tion of primitive cells in melanoma sug-
gests that these cells have inherent 
death-defying mechanisms that make 
their eradication exceedingly challeng-
ing with current therapeutics and may be 
the root cause of recurrences. However, 
the definitive identification of melanoma-
initiating cells strongly indicates the need 
for new therapeutic strategies that take 
these cells into account. One potential 
strategy, as indicated by Schatton et al., 
is antibody-mediated immune destruc-
tion. Targeting this small population of Cancer Cself-renewing cells as well the bulk non-
self-renewing tumor cells will in all likeli-
hood be the most effective approach.
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